Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share

Celcuity

12/11/2025 21:11

Overview

Celcuity Q3 adjusted loss per share and adjusted net loss beat analyst expectations

Company's operating expenses increased to $42.8 mln in Q3 2025

Celcuity on track to submit NDA for gedatolisib in Q4 2025

Outlook

Celcuity expects topline data from PIK3CA mutant cohort in late Q1 2026 or Q2 2026

Celcuity plans to submit NDA for gedatolisib in Q4 2025

Result Drivers

FINANCIAL STRATEGY - Convertible senior notes and term loan facility amendments strengthen capital structure

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Adjusted EPS
Beat
-$0.78
-$1.02 (7 Analysts)
Q3 EPS
-$0.92
Q3 Adjusted Net Income
Beat
-$37.20 mln
-$43 mln (7 Analysts)
Q3 Net Income
-$43.80 mln
Q3 Operating Expenses
$42.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Celcuity Inc is $78.00, about 1.5% below its November 11 closing price of $79.17

Press Release: ID:nGNX9HLwC2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)